Group 1 - New Source (stock code: 300109.SZ) held an investor meeting on February 6, 2023, in Shanghai, attended by 37 institutions including Shenwan Hongyuan and Everbright Securities [2][15] - Since 2026, 18 A-share listed companies from Henan have received institutional research, with Xiangyu Medical leading with 208 institutions participating [16][23] - The demand for core products, particularly PVP series products and their applications in emerging fields, was a major focus during the meeting [3][17] Group 2 - New Source is a leading high-tech enterprise in the research, development, and production of PVP series products, with a total domestic production capacity of 57,000 tons per year, accounting for 53% of global capacity and a 34% global market share [18] - PVP is widely used in various sectors, including daily chemicals, pharmaceuticals, food and beverage, materials, and new energy, with significant applications in solid-state batteries and photovoltaic cells [18][4] - The company expects to sell approximately 4,000 tons of PVP in the new energy sector by 2025, with a projected 20% increase in 2026 [4][19] Group 3 - The price of PVP products has been affected by rising raw material costs due to the European energy crisis and the Russia-Ukraine conflict, leading to increased prices and profit margins, which are not expected to be sustainable [5][19] - Another core product, Euriz (PVM/MA), has a high single-ton price with a gross margin of approximately 60%-70%, with expected shipments of about 900 tons in 2025 [20] - New Source has made strategic investments in five cell and gene therapy companies to enhance its competitive edge in the precision medical field [20][21] Group 4 - New Source's invested companies are progressing well, with one product entering NDA approval and several others in clinical stages, indicating potential for future growth and IPO opportunities [21] - The company's governance structure is relatively decentralized, with major shareholders expressing confidence in the long-term development of the company and intentions to increase their holdings [21][22] - Institutional interest in Henan-listed companies reflects recognition of their investment value, with many companies being leaders in their respective sectors [25]

智通财经APP获悉，浙商证券发布研报称，马斯克旗下Neuralink首款产品Telepathy预计在今年量产，目 前超10000人申请体验。Neuralink现估值超90亿美金，公司愿景是增加沟通带宽，提高交流效率，联接 人脑与AI。在未来，假设交流带宽将成为生物与技术之间的瓶颈，普通人将通过脑机接口实现与AI的 交流和复杂机械的操控。政策端，我国脑计划十年规划(2021-2030)进入下半场关键落地期，脑机接口成 为新质生产力未来产业之一，迎政策东风。建议关注脑机接口与大模型、具身智能技术深入融合。 浙商证券主要观点如下： Neuralink的首款产品Telepathy(心灵感应)预计在今年量产，目前超10000人申请体验 Telepathy聚焦"大脑功能正常，但运动/交流通路断裂"的重症群体，例如脊髓损伤、渐冻症患者。量产 的三个重要条件——N1性能提升、手术安全性提升、成本降低：1)预计2026年N1设备电极数量从1000 个增加到3000个，提升神经信号的接收量。2)针对手术流程，未来将直接穿过包裹大脑的硬脑膜植入电 极线的技术，可降低手术的侵入性，减少风险，降低感染隐患。3)第二代设备将电极植入速度 ...

Group 1 - The core viewpoint of the article highlights the increasing investment and research activity in the brain-computer interface (BCI) industry in China, with a focus on key companies and patent trends [1][4][5] Group 2 - The research and development investment in the BCI industry by listed companies in China is steadily increasing from 2020 to 2024, indicating a strengthening of R&D efforts [1] - The number of patent applications in China's BCI industry showed a steady growth trend, peaking at 258 applications in 2021, followed by a decrease to 209 applications in 2024 [4] - Tianjin University is identified as the leading patent applicant in the BCI sector, with a total of 126 related patents, followed by South China University of Technology and Xi'an Jiaotong University with 80 and 78 patents respectively [5][7] - The most popular technology patents in the BCI industry are in the category of electrical digital data processing (G06F), with a total of 1,013 patents, followed by diagnostic and surgical technologies (A61B) with 712 patents, and specific computing models (G06N) with 313 patents [8]

证券研究报告 Neuralink带来的启示 ——脑机接口系列报告 行业评级：看好（维持） n Neuralink带来新启示：脑机接口有望成为人与机器交流的首选，触达更广阔市场。 n 脑机接口国内政策与产业窗口期共振，中国临床案例数大幅提升。 n 脑机接口与大模型、具身智能技术深入融合，大幅推进应用落地速度。 2 2026年2月 分析师 刘雯蜀 分析师 郑毅 分析师 刘静一 邮箱 liuwenshu03@stocke.com.cn 邮箱 zhengyi@stocke.com.cn 邮箱 liujingyi@stocke.com.cn 证书编号 S1230523020002 证书编号 S1230524070002 证书编号 S1230523070005 • 核心观点 Ø Neuralink的首款产品Telepathy（心灵感应）预计在今年量产，目前超10000人申请体验。Telepathy聚焦 "大脑功能正常，但运动 / 交流通路断裂" 的重症群体，例如脊髓损伤、渐冻症患者。量产的三个重要条件——N1性能提升、手术安全性提升、成本降低：1）预计2026年N1设备电极数量从 1000 个增加到 3000 个，提升神 ...

行 业 297 机械设备 2026 年 02 月 08 日 研 究 中央政治局集体学习聚焦脑机接口等未来产业技术，解 码脑机接口产业发展内核 投资要点： 认清产业本质，脑机接口是超复杂系统工程 行 业 定 期 报 告 中央政治局第二十四次集体学习将脑机接口列为未来产业重点方 向，在脑机接口明确为未来产业重点方向之后，一个更值得深入讨论 的问题是：脑机接口究竟是一类什么样的产业形态——其并非单一技 术领域，而是兼具技术高度耦合、产业链与跨学科跨度大的超复杂系 统工程，由神经科学研究、硬件制造、算法研发等多子系统构成，各 环节动态闭环且相互制约。我国当前发展该产业存在明显短板，核心 软硬件存在外部依赖形成的 "软硬分离" 问题，同时脑数据标准不 统一、算力调度分散等基础设施薄弱问题，也制约了技术迭代与产业 发展。 聚焦系统构建，多维度夯实产业发展底座 我国脑机接口产业已进入底座构建期，发展的关键并非单点技术 突破，而是完成系统整合的跃迁。需先明确国家级技术路线图并建设 脑数据国家库等共享基础设施，再建立科研、产业、区域多层级协同 机制，同时完善覆盖全生命周期的监管体系并参与国际标准制定，更 要通过高校交叉学科布局 ...

西工大团队在植入式脑机接口 \r\n\r\n 来源：国海金贝壳 脑机接口作为融合生命科学、信息技术与 人工智能 的颠覆性技术，正成为大国角逐未来产业主导权的 战略高地。 \r\n\r\n 研究领域取得新进展 \r\n\r\n 从意念操控 机械 臂、神经语言翻译，到帕金森、瘫痪等神经疾病精准诊疗，植入式脑机接口正从科幻 构想走向现实应用。 \r\n\r\n 据中国日报网消息，近日，西北工业大学常洪龙、吉博文科研团队宣布，其研发的三维锥形碳基软性大 脑皮层电极阵列取得关键突破，成功破解长期制约行业发展的脑组织损伤、信号衰减、生物相容性差等 核心难题，同时完成国际首次太空环境技术验证，为脑机接口的临床转化与航天应用开辟全新路径，彰 显我国在微机电系统（MEMS）领域的顶尖创新实力。 \r\n\r\n 针对传统微创植入式皮层电极柔软度低、与脑组织接触效果差、长期植入金属易腐蚀甚至溶解失效等关 键问题，西工大团队历经多年潜心攻关，创新研发出三维锥形碳基软性大脑皮层电极阵列。 \r\n\r\n 动物实验结果表明，该电极采集信号更加稳定，关键性能较传统金属电极提升数百倍，能够长期安全地 进行刺激调控，并可在超高场核磁共振检 ...

Core Viewpoint - The article highlights significant advancements in brain-machine interface (BMI) technology in China, showcasing breakthroughs in flexible electrode arrays and clinical applications, indicating a growing investment interest and market potential in this field [1][4][6]. Group 1: Technological Breakthroughs - A research team from Northwestern Polytechnical University has developed a three-dimensional conical carbon-based flexible cortical electrode array, addressing key issues such as brain tissue damage and poor biocompatibility, and achieving international space environment technology validation [1]. - The electrode shows hundreds of times improvement in key performance metrics compared to traditional metal electrodes, ensuring long-term safety and stability for clinical applications [1]. - The article notes that 2025 is referred to as the "year of the brain-machine interface" in China, with multiple clinical trials and innovations being reported [2]. Group 2: Investment and Market Growth - Investment enthusiasm in the BMI sector has surged, with 24 financing events recorded from January to November 2025, marking a 30% year-on-year increase, and total financing exceeding 10 billion yuan over the past five years [4]. - The "14th Five-Year Plan" has identified brain-machine interfaces as one of six future industries, indicating a strategic focus on this technology as a new engine for economic growth [4]. - The BMI market in China was valued at 3.2 billion yuan in 2024, with an 18.8% year-on-year growth, projected to reach 5.58 billion yuan by 2027, reflecting a 20% growth rate [6]. Group 3: Clinical Applications and Innovations - Ming Vision Brain Machine Technology has introduced an implantable BMI visual reconstruction system, offering new possibilities for visually impaired patients [5]. - The second invasive BMI clinical trial has achieved significant progress, transitioning from 2D screen control to 3D physical world interaction [5]. - Shanghai Brain Tiger Technology has successfully completed the first clinical trial of a fully implanted, wireless, and functional BMI product, emphasizing the technology's potential to connect life and hope [5]. Group 4: Stock Market Performance - Several BMI-related stocks have experienced significant declines, with 14 stocks showing over a 20% drop from their highs, including HaiGe Communication and PuLiTe [6][7]. - In terms of profit forecasts for 2025, nine BMI-related stocks are expected to see net profit growth, with notable increases for companies like BeiLu Pharmaceutical and LePu Medical [8].

Core Viewpoint - The A-share market has seen a significant increase in institutional research activities in 2026, with approximately 760 listed companies undergoing various institutional investigations, indicating a growing interest in quality investment targets and industry trends [2] Group 1: Institutional Research Trends - Institutional research has accelerated, with a focus on high-quality companies across sectors such as electronics, new energy, machinery manufacturing, healthcare, and information technology [2] - The research activities are characterized by a focus on companies with strong growth potential, industry competitiveness, and favorable market conditions, leading to high frequencies of institutional visits [2][3] - Key areas of interest for institutions include industry prosperity, business development strategies, overseas market expansion, capacity utilization, and performance expectations [2][7] Group 2: High-Frequency Research Companies - Six companies have been the focus of institutional research with over 10 visits each, with Jiemai Technology leading at 15 visits, followed by Taihe New Materials and Binglun Environment [3][4] - Jiemai Technology specializes in electronic packaging materials and has shown steady revenue growth, with figures of 1.301 billion, 1.572 billion, 1.817 billion, and 1.526 billion from 2022 to the first three quarters of 2025 [4] - Taihe New Materials, with 14 visits, is a leader in the domestic spandex and aramid fiber industry, while Binglun Environment, with 13 visits, operates in multiple sectors including low-temperature refrigeration and environmental heating [4] Group 3: Companies with High Institutional Engagement - Four companies have received over 200 institutional visits, with Dajin Heavy Industry leading at over 300 visits, focusing on wind power tower production and high-value offshore wind markets [5] - Dajin Heavy Industry's revenue figures from 2022 to the first three quarters of 2025 are 5.106 billion, 4.325 billion, 3.780 billion, and 4.595 billion, showing a rebound in 2025 [5] - Neipu Mining Machinery, with a focus on heavy mining equipment, and Xiangyu Medical, specializing in rehabilitation medical devices, have also seen significant institutional interest [6] Group 4: Key Focus Areas in Institutional Research - Institutions are particularly interested in the growth potential of companies, with inquiries about industry conditions and capacity utilization being common [7][8] - Jiemai Technology reported full production capacity for its core products, while Dajin Heavy Industry highlighted its overseas market strategies, particularly in Europe [8] - The overall trend reflects a strong market recognition of quality listed companies, with institutions considering fundamental factors, industry outlook, and management teams in their research [7]

Core Insights - Insurance capital management is increasingly focused on deep research of individual stocks and industries, with significant interest in A-share listed companies as indicated by over 300 companies being researched since the beginning of 2026 [1][2] Group 1: Research Trends - A total of 96 insurance companies and 32 insurance asset management companies have participated in the research of A-share listed companies since the beginning of 2026 [2] - Key players such as Taiping Pension, Changjiang Pension, and China Life Pension have conducted over 30 research sessions each within a month [2] - Regional banks and sectors like electronic components, semiconductor materials, and devices are receiving heightened attention from insurance capital [2] Group 2: Investment Strategies - Insurance capital views company research as a crucial part of investment strategy, often focusing on high-quality stocks with long-term growth potential [3] - The demand for high dividend stocks is driven by the need for stable cash flow in a low-interest-rate environment, with banks being a primary focus for insurance capital [4] - Insurance capital is increasingly adopting a dividend strategy, favoring high dividend stocks to stabilize returns amid pressure on fixed-income yields [4] Group 3: Focus on New Productive Forces - Insurance capital is aligning with long-term investments in new productive forces, particularly in technology innovation and emerging strategic industries [5] - There is a focus on investing in sectors with real technological barriers and clear business models that can deliver performance [5] Group 4: Investment Paths - For mature technology leaders, insurance capital is likely to invest directly for excess returns, while for emerging tech sectors, indirect investments through ETFs or industry funds are preferred to manage risks [6] - The insurance capital sector is particularly interested in AI-driven technology and high-end manufacturing, with a strategy to invest in companies with clear business models and strong competitive advantages [6]

Group 1 - The core viewpoint of the articles highlights the increasing interest of insurance capital in specific sectors and companies, particularly in regional banks and new productivity sectors, as indicated by their extensive research activities [1][2][3] - Since the beginning of 2026, over 300 A-share listed companies have been researched by insurance companies and asset management firms, with significant participation from 96 insurance companies and 32 asset management companies [2] - Key areas of focus for insurance capital include regional banks such as Shanghai Bank and Nanjing Bank, as well as sectors like electronic components, semiconductor materials, and devices [2][3] Group 2 - Insurance capital is increasingly favoring high-dividend stocks as a stable source of cash flow, particularly in a low-interest-rate environment, which drives the demand for equity assets [4] - The strategy of investing in high-dividend stocks is seen as a way to enhance returns and stabilize portfolios, with a focus on long-term holdings and dividend yields [4][5] - The shift towards high-dividend stocks is also a response to new accounting standards that increase profit statement volatility, making these investments more attractive [4] Group 3 - Insurance capital is aligning with the new productivity sector, which relies on technological innovation and strategic emerging industries, requiring long-term and stable capital support [5][6] - Investments are being directed towards technology leaders with clear business models and performance track records, while emerging tech sectors may be approached through industry-themed ETFs or funds to mitigate risks [6] - The focus on AI-driven technology and high-end manufacturing is expected to be central to future technological revolutions, with a commitment to direct investments in companies with strong competitive advantages [6]